GSK2831781

GSK2831781
Monoclonal antibody
Type	?
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2088304-32-7;

GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates.^[1] GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015.

^ "Archived copy" (PDF). Archived from the original (PDF) on 2015-05-01. Retrieved 2015-04-28.{{cite web}}: CS1 maint: archived copy as title (link)

[1] "Archived copy" (PDF). Archived from the original (PDF) on 2015-05-01. Retrieved 2015-04-28.{{cite web}}: CS1 maint: archived copy as title (link)

[1]